Related references
Note: Only part of the references are listed.Regulation of PD-L1 expression in the tumor microenvironment
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
Yixiao Qin et al.
MOLECULAR THERAPY-ONCOLYTICS (2021)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Involvement of TGF-β and ROS in G I Cell Cycle Arrest Induced by Titanium Dioxide Nanoparticles Under UVA Irradiation in a 3D Spheroid Model
Yuanyuan Ren et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
The role of cancer-derived microRNAs in cancer immune escape
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
Reza Alinnohannnnadi et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2020)
The 5-Ws of immunotherapy in head and neck cancer
Andrea Botticelli et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers
Ying Jiao et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
Panagiota Economopoulou et al.
CANCERS (2020)
Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck
Elie El Rassy et al.
FUTURE ONCOLOGY (2019)
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen et al.
BRITISH JOURNAL OF CANCER (2019)
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Lisa F. Licitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
CANCER Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
Rajarsi Mandal et al.
SCIENCE (2019)
Competition for nutrients and its role in controlling immune responses
Nidhi Kedia-Mehta et al.
NATURE COMMUNICATIONS (2019)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E. W. Cohen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Prospects for combining immune checkpoint blockade with PARP inhibition
Anping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu et al.
MOLECULAR CANCER (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
Daniel L. Faden et al.
ORAL ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer A Phase 2 Clinical Trial
Erminia Massarelli et al.
JAMA ONCOLOGY (2019)
Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Xianguang Bai et al.
ONCOTARGETS AND THERAPY (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Y. -P. Chen et al.
ANNALS OF ONCOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
Takuma Matoba et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Kongju Wu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Ming Yi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Regression of epithelial cancers in humans following t-cell receptor gene therapy targeting human papillomavirus-16 E7.
Nisha Nagarsheth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.
Khalil Saleh et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Ming Yi et al.
MOLECULAR CANCER (2018)
Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers
Takefumi Komiya et al.
FRONTIERS IN ONCOLOGY (2018)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
Joshua Bauml et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Shengnan Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R. Weichselbaum et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Checkpoint immunotherapy in head and neck cancers
Paul Zolkind et al.
CANCER AND METASTASIS REVIEWS (2017)
Head and Neck Cancers-Major Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual
William M. Lydiatt et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Exosomes and tumor-mediated immune suppression
Theresa L. Whiteside
JOURNAL OF CLINICAL INVESTIGATION (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
Shanthi Marur et al.
MAYO CLINIC PROCEEDINGS (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis et al.
ORAL ONCOLOGY (2016)
Radiotherapy: Changing the Game in Immunotherapy
Sandra Demaria et al.
TRENDS IN CANCER (2016)
Tumor microenvironment: Sanctuary of the devil
Lanlan Hui et al.
CANCER LETTERS (2015)
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
Claire Vanpouille-Box et al.
CANCER RESEARCH (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy
Oana Draghiciu et al.
ONCOIMMUNOLOGY (2015)
PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
Dawn E. Dolan et al.
CANCER CONTROL (2014)
HIF-α/MIF and NF-κB/IL-6 Axes Contribute to the Recruitment of CD11b+Gr-1+Myeloid Cells in Hypoxic Microenvironment of HNSCC
Guiquan Zhu et al.
NEOPLASIA (2014)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy
Kazuki Yamasaki et al.
CLINICAL IMMUNOLOGY (2011)
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Lukas Baitsch et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Combination therapy of in vitro-expanded natural killer T cells and α-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma
Naoki Kunii et al.
CANCER SCIENCE (2009)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
Jean-Pierre Pignon et al.
RADIOTHERAPY AND ONCOLOGY (2009)
T regulatory type 1 cells in squamous cell carcinoma of the head and neck: Mechanisms of suppression and expansion in advanced disease
Christoph Bergmann et al.
CLINICAL CANCER RESEARCH (2008)
Phase I study of α-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer
Tetsuro Uchida et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Share Paper
